Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 5/20 | 0.42 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9548364 | 0.98 | NOTUM (0.41) | NOTUMCYP2E1CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL4146016 | 0.89 | PPARA (0.41) | NOTUMCYP2E1CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL2121795 | 0.83 | — | — | |
| SCHEMBL459183 | 0.80 | PPARA (0.43) | NOTUMCYP2E1CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL22713680 | 0.80 | PPARA (0.36) | NOTUMPPARACHRNB2CHRNA4 | |
| SCHEMBL18256145 | 0.80 | PPARA (0.43) | PPARACHRNB2CHRNA4 | |
| SCHEMBL9548278 | 0.78 | PPARA (0.52) | NOTUMCYP2E1CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL4167077 | 0.78 | PPARA (0.42) | NOTUMCYP2E1CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL25013973 | 0.77 | PPARA (0.41) | NOTUMPPARA | |
| Hydrochloric Acid SCHEMBL9548291 | 0.77 | PPARA (0.41) | NOTUMCYP2E1CYP2A6CYP2C9CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120238488-A1 | COMPOUNDS AND METHODS FOR TREATING NEOPLASIA | PHARMACELLION LTD. (GB) | 2012-09-20 | — | — | US | disclosed |
| WO-2011029639-A2 | COMPOUNDS AND METHODS FOR TREATING NEOPLASIA | MEDEXIS S.A. (GR) | 2011-03-17 | — | — | WO | disclosed |
| EP-0451790-A1 | 3,5-disubstituted 2-isoxazolines and isoxazoles, process for their preparation, medicines containing them and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-10-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238488-A1 | COMPOUNDS AND METHODS FOR TREATING NEOPLASIA | VHL, KRAS, TP53 | NOTUM 1496/4885CYP2E1 1252/4885CYP2A6 1042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.